Table 4.

Survival of high-risk genetic subgroups in randomized, controlled clinical trials of newly diagnosed MM: effect of treatment modalities and novel drugs

FISH	N1/N2	End point	Arm 1	Arm 2	Arm 1 (%)	Arm 2 (%)	Comment	Ref
t(4;14)	26/24	3-y OS	PAD/ASCT/thalidomide*	VAD/ASCT/bortezomib*	44	66	HOVON65/GMMG- HD4	15
	98/106	4-y OS	VAD	VD	32	63*	IFM-2005	68
	21/23	2-y OS	Thalidomide*	Placebo*	67	87	TT2	18
	21/29	2-y OS	Thalidomide-TT2	Bortezomib TT3	67	97*	TT2 vs TT3	70
Del(17p)	21/16	3-y OS	VAD/ASCT/thalidomide	PAD/ASCT/bortezomib*	17	69*	HOVON65/GMMG-HD4	15
	119/54	4-y OS	VAD	V D	36	50	IFM-2005	68
Nonhyperdiploid	92	3-y OS	VTD	VMP	53	72*	PETHEMA	63
Unfavorable FISH	152/141	3-y OS	CTD	VAD-cyclophosphamide	58	56	MRC IX intensive	62
	96/90	3-y OS	CTD	Placebo MP	34	26	MRC IX nonintensive	61
	99/98	3-y OS	Thalidomide	Placebo	45	69*	MRC IX maintenance	39

Adapted from Bergsagel et al.⁵⁸

^*Significant better survival outcome.